Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis

NCT00929864 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00929864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00929864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2009
Completion date
November 30, 2012
Enrollment
869 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis